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Abstract
Background: High mammographic density is a therapeutically modifiable risk factor for breast cancer. Although
mammographic density is correlated with the relative abundance of collagen-rich fibroglandular tissue, the
causative mechanisms, associated structural remodelling and mechanical consequences remain poorly defined. In
this study we have developed a new collaborative bedside-to-bench workflow to determine the relationship
between mammographic density, collagen abundance and alignment, tissue stiffness and the expression of
extracellular matrix organising proteins.
Methods: Mammographic density was assessed in 22 post-menopausal women (aged 54–66 y). A radiologist and a
pathologist identified and excised regions of elevated non-cancerous X-ray density prior to laboratory characterization.
Collagen abundance was determined by both Masson’s trichrome and Picrosirius red staining (which enhances
collagen birefringence when viewed under polarised light). The structural specificity of these collagen visualisation
methods was determined by comparing the relative birefringence and ultrastructure (visualised by atomic force
microscopy) of unaligned collagen I fibrils in reconstituted gels with the highly aligned collagen fibrils in rat tail tendon.
Localised collagen fibril organisation and stiffness was also evaluated in tissue sections by atomic force microscopy/
spectroscopy and the abundance of key extracellular proteins was assessed using mass spectrometry.
Results: Mammographic density was positively correlated with the abundance of aligned periductal fibrils rather
than with the abundance of amorphous collagen. Compared with matched tissue resected from the breasts of
low mammographic density patients, the highly birefringent tissue in mammographically dense breasts was
both significantly stiffer and characterised by large (>80 μm long) fibrillar collagen bundles. Subsequent proteomic
analyses not only confirmed the absence of collagen fibrosis in high mammographic density tissue, but additionally
identified the up-regulation of periostin and collagen XVI (regulators of collagen fibril structure and architecture) as
potential mediators of localised mechanical stiffness.
Conclusions: These preliminary data suggest that remodelling, and hence stiffening, of the existing stromal collagen
microarchitecture promotes high mammographic density within the breast. In turn, this aberrant mechanical
environment may trigger neoplasia-associated mechanotransduction pathways within the epithelial cell population.
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Background
Although the causative mechanisms of most breast
cancers remain poorly understood, epidemiological
evidence indicates that women with radiopaque tissue
occupying over 60 % of the breast are three to six
times more likely to develop cancer than those with
predominantly radio-translucent tissue [1, 2]. As a
consequence, the proportion of radio-dense breast
tissue (commonly referred to as mammographic
density (MD)) is an important breast cancer risk fac-
tor [3, 4]. Crucially, unlike most breast cancer risk
factors, MD can be therapeutically modified. Prophy-
lactic treatment of patients with high MD with tam-
oxifen or aromatase inhibitors can reduce MD and
hence breast cancer risk, but unfortunately patient
tolerance to such long-term endocrine therapy is low
[5, 6]. As yet the structural and compositional differ-
ences between dense and non-dense breasts, and the
identity of potential therapeutic targets, remain poorly
defined [7].
Since fat-rich adipose tissue is radiologically translu-
cent, MD is determined primarily by the amount of
fibroglandular material (comprising cell-rich epithelial
and extracellular matrix (ECM)-rich stromal tissues)
[3, 8, 9]. X-ray imaging combined with haematoxylin
and eosin (H&E) staining of breast tissue implicates
stromal collagen fibrosis as a key factor in raised MD
[10, 11]. Such perturbations in ECM homeostasis may
influence epithelial cell phenotype and tumour pro-
gression [12]. Moreover, changes in collagen organisa-
tion in the tumour microenvironment, may promote
tumour initiation and progression [13]. Whilst the
unmodified H&E staining protocol is well-suited to
characterizing breast tissue architecture, it does not
specifically identify collagen [14]. Previous studies
have failed to delineate the causative mechanisms and
biological consequences of increased MD because of:
1) the use of methodological approaches which are
unsuited to detecting specific changes in micro-scale
(i.e., cellular) ECM composition, organization and tissue
stiffness and 2) inadequate control of sampling with
regards to age, menopausal status and/or localized varia-
tions in breast density.
To overcome these shortcomings, and to define clear
links between increased MD and altered breast biology,
we have developed a new collaborative workflow for
sampling localized regions of elevated density breast tis-
sue from age-matched postmenopausal women. In this
workflow, we have linked surgeon, radiologist, patholo-
gist, tissue biobank, and laboratory scientist (Fig. 1). We
use this workflow to test the hypothesis that increased
MD in recently postmenopausal women is caused by the




Twenty-two women (54–66 years) were recruited from
the Nightingale Centre breast-screening clinic. Although
this Centre is one of the largest breast clinics in the
UK, only about 30 suitable patients within this age
range undergo surgery each year. Of these patients we
were able to achieve a consent rate of 50–60 % during the
duration of the study period. The local Research Ethics
Committee approved the study, and all patients gave writ-
ten informed consent. Women on hormone replacement
therapy or who had neoadjuvant breast cancer treatment
were not included in the study cohort.
Ethics and consent statements
These studies fall under the ethics approvals for the
MCRC Biobank, which is licensed by the Human Tissue
Authority (licence number 30004) and has been ethically
approved as a research tissue bank by the South
Manchester Research Ethics Committee (Reference 07/
H1003/161 + 5). Written informed consent was obtained
at the time of tissue collection.
Study workflow
All of the study participants were characterised for
breast cancer risk by oestrogen receptor (ER), human
epidermal growth factor receptor 2 (HER-2) and breast
cancer gene (BRCA) status – none of the individuals
recruited were BRCA-positive. A clinical radiologist
assessed digital mammograms from each patient, and
identified the area of highest radiographic density. All
studies were performed on tissue situated at least 4 cm
distant from any neoplasia. There is clear evidence from
assessments of adipokine expression, genetic changes,
mechanical properties, and radiofrequency characteris-
tics, that tissue distant from the tumour margin will not
be subject to a field change and hence can be considered
to be benign [15–18]. Following surgery, highlighted
tissue areas (5–10 mm3) were sampled from the area of
high radiographic density in the resected breast, by a
clinical histopathologist.
The samples were prepared for histological analysis of
tissue architecture, and amorphous and aligned fibrillar
collagen, by H&E, Masson’s trichrome and Picrosirius
red (PSR) staining, respectively. MD was quantified by
image analysis (Volpara® breast density [19]), validated
against visual estimation recorded on a visual analogue
scale (VAS) by a single experienced assessor. In six indi-
viduals with low and six with high MD (Table 1) micro-
mechanical analysis was performed on sections cut from
frozen tissue samples. Subsequently, ultrastructural and
proteomic analyses were carried out on six tissue sam-
ples (n =3/group). Tissue samples were assessed by a
histopathologist to confirm the absence of neoplasias.
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Mammographic density
For each patient, mediolateral oblique (MLO) and cra-
niocaudal (CC) digital mammograms were processed by
Volpara® to compute the percentage of the breast vol-
ume occupied by dense tissue [19, 20]. They were also
assessed by an experienced radiologist who recorded the
percentage of the breast area occupied by dense tissue
on a VAS.
Tissue histology
H&E and Masson’s trichrome staining were used to as-
sess cellularity, stromal and fat content and the
Fig. 1 A novel workflow for sampling radio-dense breast tissue. A radiologist identified regions of elevated radiographic density in digital
mammograms which were then excised by a pathologist prior to histological characterization of collagen abundance and organization in
all 22 patients. CC craniocaudal view, MLO mediolateral oblique view. Following stratification of patients into low and high mammographic
density (MD) groups (by Volpara® score), in regions of the tissue at least 4 cm from any tumours the molecular, ultrastructural and micro-mechanical
drivers of MD were characterized as individuals with low (n = 6) and high (n = 6) MD by atomic force microscopy (AFM). Three of each of the samples
with low and high MD (low-MS, and high-MS) were also analysed by mass spectrometry (mass spec). AFM atomic force microscopy
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abundance of amorphous collagen [21, 22]. Tissue sam-
ples were bisected, one half was fixed overnight in 4 %
paraformaldehyde in PBS before processing to wax with
an ASP6025 automated tissue processor (Leica, Newcas-
tle, UK). Sections (3 μm thick) were adhered to posi-
tively charged slides, before dewaxing and methanol
processing prior to staining. Following batch staining
with the histology stains H&E and Masson’s trichrome,
mounted sections were imaged sequentially using an
SCN400 digital slide scanner (Leica, Newcastle, UK),
with a Leica NA Plan Apo × 20/0.75 objective. Slides
were only scanned in areas where specimen tissue was
present. Resulting images (0.46 μm/pixel resolution)
were saved in the MIRAX format. Image analysis was
performed with custom-written rule sets for the Tissue
Studio 3 software package (Definiens, Munich,
Germany) [23]. More specifically, images were thre-
sholded using the hue, saturation and brightness
colour space with epithelial regions identified as the
areas of lowest brightness and hue, adipose regions as
areas of highest brightness and hue and stromal re-
gions as intermediate values.
Fibrillar collagen abundance and organisation
As ECM organisation, and not just abundance, plays a
key role in determining the mechanical properties of tis-
sues [24], we additionally stained breast tissue samples
with PSR (1 h incubation with 0.1 % sirius red F3BA in
saturated aqueous picric acid at pH 2 followed by clear-
ing in 0.1 % HAc, dehydration and mounting in DPX)
[25]. When visualised under cross-polarised light, the re-
sultant collagen-associated birefringence can be semi-
quantitatively assessed against total tissue area [26, 27].
To clarify whether this PSR enhanced birefringence was
induced by collagen fibrils alone [28], or only by assem-
bled collagen fibrils aligned into fibres [25], we assessed
the ability of PSR/polarised light microscopy to visualise
aligned collagen I fibrils in young Wistar rat tail tendon,
and in non-aligned fibrils reconstituted in vitro from
bovine collagen I (Thermo Fisher Scientific Ltd.,
Loughborough, UK). Collagen fibril gels were formed
at 37 °C in a hydrated atmosphere, with a gelation
time of approximately 30 minutes [29]. Additional quanti-
tative analyses of collagen orientation (coherency) were
conducted on PSR stained images using a well-established
methodology [105].
Ultrastructure
We have previously shown that AFM can readily image
nano-scale structural detail in unstained tissue cryosec-
tions [30]. We applied this technique to characterise the
effects of MD on fibrillar collagen organisation in
peri-ductal tissues, and to compare the ultrastructural
architecture of collagen fibrils in rat tail tendon and
reconstituted gels. The other halves of the bisected
breast tissue samples, along with the rat tail tendon
Table 1 Clinical and mammographic assessment of the patient cohort
Disease status of patients assessed histologically. Also indicated are the age, height, and weight of each individual as well as the high (red) and low (blue)
individuals selected for both micromechanical and proteomic analyses (crossed boxes). BMI body mass index, DCIS ductal carcinoma in situ, HER-2 human
epidermal growth factor receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, neg negative, ER oestrogen receptor, pos positive, RRMx
risk-reducing mastectomy, VAS visual analogue score
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and reconstituted collagen fibrils were embedded in
optimal cutting temperature cryo-sectioning media
and snap frozen into a 2.5-cm mould with liquid ni-
trogen cooled isopentane [30]. Frozen sections were
then cut to a nominal thickness of 5 μm in a cryostat
microtome at −20 °C, air dried, washed in distilled
H2O and stored at 4 °C. Subsequently these cryosec-
tions were imaged by a Bioscope Catalyst utilising
Bruker’s ScanAsyst PeakForce mode (Bruker, Coventry,
UK), a Bruker Scanasyst Air triangular silicon nitride can-
tilever (nominal spring constant of 0.2 N/m and a pyram-
idal tip of nominal radius of 2 nm). Height and amplitude
images were captured at two scan sizes. For smaller scan
areas, 10 × 10 μm was assessed at a scan frequency of 0.25
Hz and a sampling frequency of 1024 × 1024 (for a lateral
spacing of 9.76 nm), whereas for large areas 150 x 150 μm
was assessed at a scan frequency of 0.01 Hz and a sam-
pling frequency 4992 x 4992 (for a lateral spacing of
30.05 nm).
Control collagen samples
Rat tail tendon was extracted from intact tail following
sacrifice of 12-month-old Wistar rats. Whole collagen
fibre bundles were removed from the tail, fixed over-
night in 4 % paraformaldehyde in PBS before processing
to wax (as before). Sections (3 μm thick) were adhered
to positively charged slides and dewaxed before staining
or AFM analysis. Re-constituted collagen gels were made
from Bovine Collagen I (Gibco, Warrington, UK) by
treating collagen at 5 mg/mL with 1 N NaOH on ice to
produce a total volume of 2 ul. This liquid suspension
was placed onto a charged slide where it was allowed to
dry down overnight and rinsed with distilled water
before being assessed for collagen fibril abundance and
organisation by both polarised light microscopy of PSR
stained sections and AFM..
Tissue micro-mechanics
Micro-indentation of rat tail tendon reconstituted colla-
gen fibrils and peri-ductal breast tissue (from six pa-
tients with low MD and six with high MD) was carried
out using 5 μm thick cryo-sections and a Bioscope
Catalyst AFM (Bruker, Coventry, UK) mounted onto an
Eclipse T1 inverted optical microscope (Nikon, Kingston,
UK) fitted with a spherically tipped cantilever (nominal
radius and spring constant of 1 μm and 3 Nm−1 respect-
ively: Windsor Scientific Ltd., Slough, UK,) running
Nanoscope Software v 8.15 (Bruker, Coventry, UK). The
local reduced modulus was determined for each of 400
points in a 25 × 25 μm region, indented at a frequency of
1 Hz with lateral spacing of 1.25 μm. The extend curve
was used in conjunction with a contact-point-based
model to calculate the reduced modulus for each inden-
tation [31]. For each biological sample, three 25-μm2
regions, and hence 1,200 force curves, were collected.
Post hoc analyses of force curves were performed using
Nanoscope Analysis v 1.40 (Bruker, Coventry, UK),
whereby a baseline correction was applied to each
curve before a force fit was applied using the Herzian
(spherical) model and a maximum force fit of 70 %.
Once all 400 force curves had been generated, quality
control was applied, whereby any force values falling
more than two standard deviations away from the
mean value were discarded in order to account for
failed indents. In general fewer than 10 % of force
curves were excluded. (data not shown). Note that in
the same breast samples, there was no significant differ-
ence between the reduced modulus of 5-uM-thick sec-
tions (440 kPa ± 12) and 20-uM-thick sections (450
kPa ± 17, n = 1,200, p >0.0001).
Proteomics
Frozen tissue (20 mg) from three individuals with low
and three with high overall MD was used to assess
protein content by mass spectrometry conducted in the
Faculty of Life Sciences Biological Mass Spectrometry
Facility (Bio-MS). Tissues were disrupted using a Fisher
120 sonic dismembrator (Thermo Fisher, Cramlington,
UK) and resuspended in 8 M urea 0.1 M Tris HCl
pH8.5 [32]. The solubilised protein level was quantified
using a Direct Detect system (Millipore, Billerica, MA,
USA) and 25 ug were taken for subsequent digestion.
Proteins were then digested using a variant of the filter-
aided sample preparation (FASP) method [33] whereby
proteins were solubilised in urea instead of SDS. In brief,
proteins were reduced with dithiothreitol and alkylated
with iodoacetamide in the presence of 8 M urea in a
Micron 30 kDa centrifugal unit followed by pre-
digestion with LysC in 6 M urea before digestion with
trypsin in 1.5 M urea. The resultant peptides were
desalted into 0.1 % formic acid in 5 % acetonitrile using
Poros R3 reversed phase chromatographic media (Life
technologies, Carlsbad, CA, USA) housed in 0.20-um
polyvinylidene fluoride (PVDF) filter 96-well plates
(Corning, New York, NY, USA). Liquid chromatography–
mass spectrometry (LC-MS/MS) was performed using an
Orbitrap Elite™ Hybrid Ion Trap-Orbitrap Mass Spec-
trometer coupled with a nano U3000 chromatography sys-
tem (both Thermo Fisher, as before). The data produced
was quantified using Progenesis LC-MS (Non-Linear Dy-
namics, Newcastle, UK) and identified using Mascot
(Matrix Science, London, UK). Proteins identified by mass
spectrometry (MS) were allocated to categories according
to their Gene Ontology (GO) cellular compartment anno-
tation, and enrichment of GO terms was assessed using
enrichment analysis in Cytoscape (NRNB, Bethesda,
Maryland, USA) [34].
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Statistical analyses
The non-parametric Mann–Whitney U test was applied
to determine significance (Graphpad Instat La Jolla, CA,
USA). Values are reported as mean ± SD. Analysis of
AFM data was conducted using SPSS 20 (SPSS, Chicago,
IL, USA). Normal distribution was confirmed by q-q
Fig. 2 Assessment of mammographic density and tissue architecture. a, b There was a significant correlation between two common methods of
assessing mammographic density (MD), visual analogue scale (VAS) and Volpara® (a). b H&E-stained paraffin section of resected breast tissue
(low MD). Adipose, epithelial and stromal tissues are highlighted in red, blue and green respectively. c–e Tissue architecture (adipose, epithelial
and stromal content) was not significantly correlated with MD
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plot. One-way analysis of variance (ANOVA) was used
to compare means. For all analyses, a value p <0.05 was
considered statistically significant.
Results and discussion
Patient cohort and assessment of MD
A cohort of 22 postmenopausal women (59.7 ± 3.2 years)
was recruited (Table 1). Compared with previous studies,
this cohort was well-defined with regards to age and
menopausal status [10, 11]. In 18 patients, cancers were
diagnosed by a combination of clinical and radiological
investigation (bilateral mammography and ultrasound
scanning). Histological confirmation of malignancy in
these individuals was obtained from a clinically derived
image-guided core biopsy. No patients had metastases
or cancer cell involvement with the breast skin or chest
wall. For this study, we only analysed biopsies that were
confirmed to be neoplasia-free by a clinical histopatholo-
gist following examination of H&E and Masson’s
trichrome stained sections. The samples studied were on
tissue situated at least 4 cm distant from any neoplasia.
Four women did not have a diagnosis of breast malig-
nancy, and were undergoing bilateral risk-reducing
mastectomy.
An experienced consultant breast radiologist assessed
MD. Density ranged from 11–69 % using a VAS, while
percent breast density measured by automated volumet-
ric breast density software (Volpara®) varied between 3 %
and 25 % (Table 1). There was a significant correlation
between these two methods of measuring MD (r2 = 0.70,
p <0.001) (Fig. 2a). Volumetric approaches for measuring
breast density (as implemented by Volpara®) have been
extensively validated against objective reference standard
measurements obtained from magnetic resonance
imaging (MRI) [35, 36] and the potential benefits of
using multiple measures of MD have previously been
highlighted [4]. In our study, the VAS and Volpara® ap-
proaches identified the same individuals with high MD
(Table 1: patients 2, 4 and 15). Moreover, there was no
significant difference between MD (as measured by ei-
ther technique) in women diagnosed with a tumour and
those who were tumour-free, or significant correlation
between MD and tumour size (data not shown). In
addition, MD was also unrelated to tumour size (MD by
Volpara®, r2 = 0.150, p = 0.57; MD by VAS, r2 = 0.018,
p = 0.95, data not shown).
Together these studies identified regions of normal,
non-neoplastic breast tissue of varying MD, which were
used for further analysis. This element of the study de-
sign is key as it demonstrates that we are assessing nor-
mal tissue rather than tissue remodelled by tumour cells.
Moreover, the expression of adipokines and fatty acids is
reported to differ significantly in the peri-tumour area
compared to distant tissue [15], indicating that sampling
regions 4 cm distant from the tumour will ameliorate
any effect of the tumour on the normal tissue sampled.
Also, genetic changes occurring distant from HER2-
amplified breast cancers result from tumour cell con-
tamination rather than a field change [17]. Body mass
index (BMI), a strong indicator of overall adiposity and
therefore breast fat content, was not significantly corre-
lated with MD in our cohort, suggesting that adipose
content is not a mediator of MD in these individuals
(Table 1).
MD correlates with collagen birefringence
To assess the potential role of stromal and parenchymal
remodelling in driving increased MD, we quantified
epithelial, adipose and stromal content in H&E-
stained sections using automated intensity segmenta-
tion (Fig. 2b–e). Although the proportion of these tis-
sues varied markedly between individuals (epithelial: <1 %
to >10 %, adipose: <10 % to >80 %, stromal: <20 %
to >80 %) there was no evidence of a relationship be-
tween tissue micro-architecture and MD (r2 = 0.0004 to
0.0053, p = 0.484 to 0.494). These observations contrast
with the findings of previous studies, which reported a
positive correlation between MD and fibroglandular
(epithelial and stromal) content in the breasts of pre- and
postmenopausal women aged 20–83 [9] and 40–82 years
[8], respectively. By controlling for age and menopausal
status, our study suggests that in the absence of larger-
scale remodelling events, loss of stromal ECM homeosta-
sis may drive changes in MD.
Previous studies have identified stromal collagen de-
position, as quantified by Masson’s trichrome [37] or
H&E staining [10] as a mediator of MD. However, in the
present cohort (Fig. 3a, b), we could find no correlation
between MD and collagen content as determined by
Masson’s trichrome (r2 = 0.0053) (Fig. 3c). This disparity
may again be due to the contrasting age and menopausal
status of the patients in the studies. In contrast to the
narrow age range (12 years) in our cohort, others have
drawn their tissue samples from individuals aged 15–90
years [37]. Moreover, in another study using individuals
of a 54–75-year age range, collagen abundance was
assessed using a semiquantitate scoring technique on tis-
sue sections stained with non-specific H&E [10]. It is
important that this architecture may not be maintained
in regions of lower local radiographic density.
Although Masson’s trichrome is thought to specifically
stain amorphous collagen, it is generally accepted that
PSR-enhanced birefringence in tissue sections is specific
for fibrillar collagens only [22, 25]. Here, we identified a
significant positive correlation between MD and local-
ized, PSR-enhanced, collagen birefringence in peri-
ductal stroma (i.e., within 20 μm of the ducts) (Fig. 3d
and D: r2 = 0.8658, p <0.0001), but not in perilobular or
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Fig. 3 (See legend on next page.)
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distal stroma (data not shown, perilobular: r2 = 0.1006,
p = 0.33; distal stroma: r2 = 0.2381, p = 0.14). Together,
these results suggest that the extent of patient MD in
non-neoplastic tissue correlates with the amount of
collagen birefringence revealed by PSR staining.
Collagen birefringence correlates with fibril alignment
In common with many ECM structural proteins, fibrillar
collagens (in particular collagens I and III) function as
supra-molecular assemblies where monomers form fi-
brils, which in turn form fibres [13]. To characterize the
effects of collagen organization on PSR-enhanced bi-
refringence, we stained and visualized both collagen gels
and rat-tail tendon cryosections. Despite being com-
posed entirely of collagen I, PSR-stained collagen gels
exhibited minimal birefringence under polarised light
(Fig. 4a). In contrast, PSR-stained rat-tail tendon colla-
gen was highly birefringent (Fig. 4b). Given the similar-
ities in composition between the two systems, we
reasoned that PSR-enhanced birefringence is critically
dependent on either macro-molecular assembly of colla-
gen monomers into fibrils, or supra-molecular assembly
of fibrils into fibres. As the spatial resolution of conven-
tional optical microscopy is insufficient to visualize indi-
vidual collagen fibrils, we imaged collagen gel and
tendon collagen cryosections by AFM [30]. Rather than
containing amorphous collagen, both gel and tendon
were composed of collagen fibrils (readily identified by
their characteristic gap/overlap banding pattern) with
similar periodicities of approximately 66 nm (inset in
Fig. 4c and d and panel e). However, whilst the
birefringent-negative fibrils in the gel were both hetero-
geneous in diameter and non-aligned, the birefringent-
positive tendon fibrils were homogeneous in diameter
and highly aligned (Fig. 4f ). These results suggest that
the PSR-enhanced collagen birefringence arises from fi-
bril organisation with regards to its diameter and/or
alignment, rather than its abundance.
We further explored this potential relationship by
directly measuring the coherence (alignment) of birefrin-
gent collagen within peri-ductal regions in tissue
sections taken from six patients with low and six with
high MD (Fig. 3e, f ) [105]. Collagen coherency was
significantly higher in patients with high MD (Fig. 3g,
Additional file 1: Figure S1). These results fit with previ-
ously published observations of tumour-associated colla-
gen signatures in breast tumours, which suggest that
ECM organisation is altered at the tumour-stroma
boundary in more malignant tumours [100].
Peri-ductal tissue contains large-diameter, stiff collagen
fibres
Having identified localized PSR-enhanced birefringence
as the key marker for raised MD, we used AFM imaging
and force spectroscopy to determine if it correlated with
collagen fibril reorganization and local micro-stiffness.
Peri-ductal collagen fibrils in breast derived from pa-
tients with high, but not low, MD were organized into
aligned fibrous bundles (Fig. 5a, b). The bundles were
evident in tissue samples from each of the patients with
high MD and were remarkably homogenous in morph-
ology (approximately 100-μm-long and 10-μm-wide;
Fig. 5bi). They were connected to surrounding material
by a network of smaller-diameter fibrils/fibres (Fig. 5bii).
However, few comparable bundles were present in the
peri-ductal tissue of individuals with low MD (Fig. 5ai).
Tissue from these individuals was characterised by the
presence of loose collagen aggregates (Fig. 5aii). These
findings are consistent with studies suggesting that colla-
gen fibrils are best resolved dehydrated, with rehydration
performed when nano-mechanical measurements are
required [39, 40].
Fibrillar collagens are important mediators of tissue
tensile strength and stiffness, while changes in tissue
mechanical properties are associated with cancer initi-
ation and invasion [41–44]. We therefore assessed the
functional consequences of peri-ductal collagen remod-
elling in six patients with high and six with low MD
using localized AFM indentation of tissue cryosections
(Fig. 5c–f ). Mean reduced modulus (and hence localized
tissue stiffness) varied between 100 kPa and 820 kPa
(median 247 kPa) in patients with low MD, compared
with 200 kPa to 1380 kPa (median 611 kPa) in patients
with high MD (Fig. 5e). These values are in agreement
(See figure on previous page.)
Fig. 3 Relationship between mammographic density and amorphous and fibrillar collagen contents. a Masson’s trichrome staining (amorphous
collagen: blue/green, epithelial tissue: blue/black). Bold numbers denote Volpara score®, anonymous patient identifiers are reported in parentheses.
b, Serial paraffin sections stained with Picrosirius red (PSR) and visualised by polarised light microscopy. Note that the boxed regions (a) correspond
to the areas corresponding to the enlarged PSR regions in b. For each patient, three regions of the tissue shown in a were analysed in more detail
by PSR staining and by Masson’s trichrome staining. However for clarity, only one region is shown in a and b. c Amorphous collagen content as
visualized by Masson’s trichrome staining was not correlated with mammographic density (MD). Note that for the quantitative data provided (c and d),
we analysed (as above) three regions of tissue for each sample, though for clarity only one region is shown in a. d Fibrillar collagen content was
significantly correlated with MD. e, f Polarised light microscopy of PSR-stained sections assessed using OrientationJ: e low MD, f high MD. Colour
is indicative of fibre alignment. g Coherency of organised fibrillar collagen was significantly increased in high MD (0.38 % ± 0.11) compared to low
MD (0.21 % ± 0.11, p <0.001, n =18)
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Fig. 4 (See legend on next page.)
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with recent work showing that when indented at lower
loading rate, tissues with a high collagen fibre content
have a reduced modulus in the range of hundreds of ki-
lopascals [45]. In this analysis we utilised 5-μm-thick
cryosections. Although these are relatively thin sections,
it is widely accepted that if the indentation depth is
smaller than 10 % of the sample thickness, the effect of
the substrate can be ignored [46]. In this study the in-
dentation depth was 20 nm or less (as is required by
PeakForce QNM: [90, 91] and we observed no statistical
difference in reduced modulus between 5-μm-thick and
20-μm-thick sections (data not shown). The absolute
modulus values that we report are however, considerably
higher than those reported for fresh breast tissue [92, 93].
These disparities may be attributable to many factors in-
cluding sample preparation (freezing and dehydration),
probe characteristics (we use a large diameter tip, which is
unlikely to puncture soft tissue [94] and the depth and lo-
cation of the indentation (our cryo-section technique
allows us to measure localised mechanical changes within
the peri-ductal region).
Crucially however, whilst it is well-established that ab-
solute values for indentation moduli are strongly influ-
enced by the specific experimental conditions (even for
the same tissues [95–97], our AFM system measures
relative modulus values which are: 1) comparable with
previous studies on the micro-mechanics of tendon [98]
and skin [99] and 2) consistently and significantly higher
in peri-ductal breast tissue of high MD. The cause of
this peri-ductal stiffening may be due to the influence of
differential crosslink formation between the two groups
as a factor in local breast tissue stiffness, however, previ-
ous studies both in vitro (collagen scaffold formation)
and in vivo (tendon stiffness) have shown that collagen
fibril structure and organisation mediates the mechanical
properties of materials [47, 48]. Collectively, these results
suggest that the increased stiffness of breasts of high
MD is associated with remodelling of collagen fibrils
into large-diameter peri-ductal stiff fibres, rather than
the fibrotic deposition of additional collagen.
High MD is associated with an increased abundance of
collagen-organising proteins
To identify potential causative mechanisms of raised
MD, we used mass spectrometry to characterise the
proteomes of resected breast tissue from the patients
with low and high MD (n = 3/group). Proteomic analysis
of ECM has been done in a few other tissues [106].
Moreover, an extensive set of ECM proteins has been
revealed within rat mammary gland preparations [101,
102], and in tumours arising from MDA-MB-231 cell
lines [103]. We have identified a significant number
of similar ECM proteins within the human breast
(Additional file 2: Table S1), and compared the pro-
teomes of breast tissues isolated from different hu-
man samples with either low or high MD (Fig. 6,
Additional file 3: Table S2). Eight proteins with raised
abundance were present in tissues from patients with
high MD, and a further sixteen proteins were less
abundant. Although the analysis identified proteins
that are markers of breast and other cancers, there
was no proteomic evidence of a relationship between
MD and collagen fibrosis.
Neo-collagen fibrillogenesis is associated with expres-
sion of proteins such as the collagen I and III alpha
chains, collagen processing enzymes BMP-1/tolloid C-
proteinases and ADMATS N-proteinases, and regulators
of fibrillogenesis including collagen V and XI, integrins
α5β1 and α2β1, tenascin-X, thrombospondin 2, cartilage
oligomeric matrix protein, matrilins, perlecan and the
small leucine-rich proteoglycans [49]. Instead, in tissue
derived from patients with high MD in our study, mass
spectrometry revealed increased levels of proteins that
control collagen fibril interactions, diameter and cross-
linking, including collagen XVI and periostin (1.3-fold
and 1.2-fold increase, respectively) [50–52]. Collagen
XVI and periostin have previously been detected in
breast ECM, but this is the first time that their levels
have been found altered in high vs low human MD
breast tissue [101, 103]. In addition there was a de-
creased abundance of the ECM protease inhibitors
Serpin B6 and coagulation factor XIII A [53, 54].
Collagen XVI is a FACIT collagen that interacts with
cells, and other ECM components including elastic-fibre-
associated proteins [55]. Although this adaptor protein,
which connects and organises large fibrillar networks, has
not previously been associated with breast cancer, upregula-
tion of collagen XVI is associated with cell invasiveness and
proliferation in glioblastoma and oral cancer [56, 57].
Moreover, the heparin-binding glycoprotein periostin,
(See figure on previous page.)
Fig. 4 Picrosirius red-enhanced collagen birefringence in non-aligned collagen gels and aligned tendon collagen. a, b Bright field (left) and
polarised light microscopy (right) of PSR-stained cryosections cut from reconstituted collagen gels (a) and rat tail tendon (b). c, d Atomic force
microscopy (AFM) height maps of collagen gels (c) and tendon (d). Collagen alignment and periodicity (white arrows) can be readily determined
from fast fourier transform (FFT) of AFM amplitude images. Inset position of the fast fourier transform (FFT) signals corresponding to collagen peri-
odicity (diffuse circles for the gel and discrete lines for the tendon) are indicated by arrows. e AFM-derived collagen periodicity. f Micro-mechanical
stiffness (modulus (MPa)) of in vitro (gel) (255 kPa ± 0.91) and in vivo (tendon) assembled collagen (869 kPa ± 0.90, p <0.005)
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which is commonly found in tissues under high mechanical
load, regulates collagen fibril morphology and potentially fi-
bril crosslinking via BMP1- mediated activation of LOX
[50, 52, 58, 59]. Periostin is overexpressed in most breast
cancers, where it enhances angiogenesis and tumour
progression, and recruits Wnt ligands to maintain cancer
stem cell maintenance [60, 61]. Thus, proteomic analysis
reveals that high MD is associated with the de novo expres-
sion of proteins that are involved with ECM remodelling
and which might contribute to a cancerous phenotype.
Fig. 5 Ultrastructure and micro-mechanical stiffness of peri-ductal tissue in patients with low and high mammographic density (MD). a, b Atomic
force microscopy (AFM) height maps of tissue of low (a) and high (b) MD captured at 150 × 150 μm and a sampling frequency of 4992 × 4992.
Arrows indicate collagen fibril bundles (fibres) in high MD breast tissue. aii, bii Magnified regions corresponding to the boxes in ai and bi. Low
MD tissue, as depicted (ai and aii) was characterised by the presence of loose fibrillar collagen bundles. However (bi, bii), the central large fibrillar
bundle is connected to surrounding tissue by a network of fine fibrils (150–450 nm diameter). c, d H&E-stained breast biopsies from patients with
low and high MD. Mechanical data were measured by atomic force microscopy (AFM) indentation (20 × 20 points) in 25-μm2 peri-ductal regions,
shown in blue (low MD) and red (high MD) boxes. e, f Peri-ductal regions were significantly stiffer in patients with high MD compared with low
MD (n = 12 patients, p <0.005)
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Conclusions
Here we provide initial data showing that, in a recently
postmenopausal patient cohort, neither large-scale tissue
remodelling between epithelial and stromal tissues, nor col-
lagen deposition as assessed by both Masson’s trichrome
staining and mass spectrometry, correlates with MD. In-
stead, the peri-ductal regions of high MD breast tissue are
characterized by: 1) the remodelling of collagen fibrils to
form large collagen fibres, evident from both polarised light
microscopy of PSR-stained sections and AFM, and 2) the
upregulation of collagen-organising molecules, which have
previously been identified as markers of breast cancer and
metastatic colonisation rather than breast cancer risk [60,
62, 63]. Thus, the architectural remodelling of fibrillar colla-
gens, rather than collagen fibrosis, may be a key molecular
driver of raised MD, although other ECM remodelling
events may also play a role. We suggest that this
organisation of collagen fibrils into collagen fibres in turn
increases the local mechanical stiffness of breast stroma.
Although we do not yet know how collagen reorganisation
into fibres in normal breast tissue may promote tumour ini-
tiation, organised collagen is a feature of human breast can-
cer. Indeed, collagen alignment within advanced cancer
(e.g., the tumor-associated collagen signature-3 TACS-3 tis-
sue architecture) is associated with disease outcome [104].
Given the limitations of the current study with regards to
the relatively small size of the patient cohort, the inclusion
of tissue from breasts that contain tumours and the highly
localised nature of the mechanical mapping, further studies
on the molecular causes of raised MD are clearly
warranted.
Finally our data demonstrate that PSR, which is a
commonly used collagen stain, is specific not for colla-
gen fibrils, as was previously assumed, but for larger-
Fig. 6 Proteomic analysis of low and high mammographic density (MD) tissue. Proteins exhibiting >2-fold difference in abundance between tissue
samples derived from patients with low and high MD. Red bars indicate greater abundance in tissue from patients with high MD: apolipoprotein D
(APOD), a breast cyst fluid component and potentially a progesterone transporter [65], which is expressed in ductal carcinoma [66]; prolactin-inducible
protein (PIP), a fibronectin-degrading aspartyl proteinase [67], which is frequently expressed in androgen receptor-positive breast tumours [68];
polymeric immunoglobulin receptor (PIGR), an epithelial cell-surface-located [69] biomarker of metastatic breast cancer [70]; zinc-alpha-2-glycoprotein
(AZGP1), which stimulates lipolysis in adipocytes and is expressed in up 50 % of human breast cancers [71]; collagen XVI alpha 1 chain and periostin
(COL16A1 and PSTN), extracellular matrix (ECM)-regulating proteins, which control collagen fibril interactions [50–52]; and two further proteins:
immunoglobulin J (IGJ) and ACTN4, which have no known links to cancer or ECM remodelling [72, 73]. Proteins with a greater abundance in low
MD tissue include: myeloperoxidase (MPO), serum markers of breast cancer including the neutrophil activity marker myeloperoxidase [74]; S100A8
and S100A9 (proinflammatory regulators [75, 76]), which play an as-yet poorly defined role in metastasis [77, 78]; C5 (a proteolytic degradation
product of complement C5 [79], S100A11), which facilitates keratinocyte differentiation; apolipoprotein C-I (APOC1), an inhibitor of lipoprotein/LDL
receptor binding [80], which may promote chronic low-grade inflammation and breast cancer [81]; inter-alpha-trypsin inhibitor heavy chain H1
(H1ITIH1), a hyaluronan binding protein [82], which is implicated in inflammation and downregulated in breast cancer [83]; HRG, histidine-rich
glycoprotein, which inhibits tumour vascularisation [84, 85]; apolipoprotein A-I (APOA1), which is reported to be protective against breast cancer
[86]; SERPINB6, an ECM protease inhibitor [54]; coagulation factor XIII A chain (F13A1), which inhibits degradation of collagen precursors [53];
glucose-6-phosphate isomerase (GPI), which modulates cancer cell phenotype [87]; apolipoprotein A-IV (APOA4) - blood plasma levels are
significantly reduced in BRCA1 mutation carriers modulate [88]; laminin subunit beta-2 (LAMB2), a component of basement membranes,
which is implicated in tumour angiogenesis [89]. Both serum paraoxonase/arylesterase 1 (PON1) and mitochondrial 60 kDa heat shock
protein (HSPD1) appear to be unrelated to either matrix homeostasis or tumourigenesis
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scale organised collagen bundles. Given the impact of
fibrotic diseases on human health, this ability to distin-
guish between structurally and functionally distinct
forms of collagen has important implications for the
interpretation of aberrant remodelling both in breast
and in diverse fibrotic tissues [64].
Additional files
Additional file 1: Figure S1. Coherence of collagen organization in
patients with low vs high mammographic density (MD). a, b Polarised
Picrosirius red images (×20) of peri-ductal stroma in an individual with
low MD (a) and high MD (b). c, d Areas assessed by OrientationJ in
individuals with low MD (c) and high MD (d). Colour coding is indicative
of angle of collagen orientation. d Coherency values for six individuals
with low vs six with high MD. (EPS 47751 kb)
Additional file 2: Table S1. Breast extracellular matrix (ECM) proteomic
data. This table shows the ECM proteins detected in our mass spectrometry
analysis of human breast tissue, plus those identified by mass spectrometry
in rat mammary tumours, and the ECM of tumours resulting from the in
vivo growth of the MD-MBA-231 breast cancer line. Green boxes indicate
proteins that were identified in the analyses, red boxes show proteins not
identified. The differences in expression may arise because completely
different samples have been used, e.g., human vs rat, and normal
human breast tissue vs a cancer line model. (DOC 124 kb)
Additional file 3: Table S2. Peptide frequencies for individual proteins
identified in the mass spectrometry analysis. This table includes accession
number, gene name and raw expression values for low and high mass
spectrometry (MD) samples. (DOC 208 kb)
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